

Quantifying bias from dependent left truncation in survival analyses of real world data

Arjun Sondhi,¹ Olivier Humblet,¹ Akshay Swaminathan¹

¹Flatiron Health, Inc.

Corresponding author: Arjun Sondhi; arjun.sondhi@flatiron.com

Disclosures: At the time of the study, all authors report employment in Flatiron Health, Inc., an independent subsidiary of Roche. All authors report stock ownership in Roche.

Funding: This study was sponsored by Flatiron Health, which is an independent subsidiary of the Roche Group.

Abstract

In real world data (RWD) studies, observed datasets are often subject to left truncation, which can bias estimates of survival parameters. Standard methods can only suitably account for left truncation when survival and entry time are independent. Therefore, in the dependent left truncation setting, it is important to quantify the magnitude and direction of estimator bias to determine whether an analysis provides valid results.

We conduct simulation studies of common RWD analytic settings in order to determine when standard analysis provides reliable estimates, and to identify factors that contribute most to estimator bias. We also outline a procedure for conducting a simulation-based sensitivity analysis for an arbitrary dataset subject to dependent left truncation.

Our simulation results show that when comparing a truncated real-world arm to a non-truncated arm, we observe the estimated hazard ratio biased upwards, providing conservative inference.

The most important data-generating parameter contributing to bias is the proportion of left truncated patients, given any level of dependence between survival and entry time.

For specific datasets and analyses that may differ from our example, we recommend applying our sensitivity analysis approach to determine how results would change given varying proportions of truncation.

1. Introduction

In many electronic health record (EHR) databases, patients are only observed if they satisfy certain entry criteria, such as having a specific number of clinic visits, or undergoing a biomarker testing procedure.^{1,2} This also occurs in prospective cohort studies where patients are enrolled after an initiating event of interest.³ In time-to-event analyses, if a patient enters the study or database after the start of their follow-up or index time, they are said to have *delayed entry*. With this sampling process, we do not observe any patients who experienced a disqualifying event (such as death) before satisfying the entry criteria, which is referred to as *left truncation*.⁴ Failure to account for left truncation by including patients in a survival analysis at their index time and accruing person-time prior to satisfying the entry criteria results in a selection bias, since patients observed in the database had to at least live long enough to qualify for entry.^{5,6}

When dealing with left truncated data, standard methods for estimating the marginal survival distribution are instead estimating survival conditional on surviving up to entry time. The most common approach for recovering the marginal distribution is *risk set adjustment*, where patients are only considered to be at risk for the endpoint of interest once they have satisfied the entry criteria. In contrast, standard methods treat all patients as at risk from the start of their follow-up or index time until their observed event or censoring time, resulting in bias. Risk set adjustment is easy to implement with standard software, and can be used with both Kaplan-Meier survival estimators and Cox proportional hazards regression models.⁷ However, it relies on the assumption that the time to the endpoint T is independent of the time to entry E , given that $T > E$. In other words, patients who entered later should have the same hazard of death as those who entered earlier. This *independent left truncation* assumption is testable. The simplest method is the coefficient test of a risk set adjusted Cox model with entry time as the sole covariate.⁸ There are also tests based on conditional Kendall's tau that may be more appropriate when the Cox model assumption does not hold.^{9 10}

In practice, however, the assumption of independence is not always satisfied. For example, in a study of mutation-positive patients with cancer identified through biomarker testing, it is possible that testing could be triggered by worsening of disease and exhaustion of standard therapies, or that patients tested earlier have better outcomes due to timely receipt of targeted therapies. If there is dependency between survival and entry time, then risk set adjustment is no longer guaranteed to unbiasedly estimate the marginal survival distribution. However, the magnitude and direction of this bias is generally unexplored in the literature. While there have been some proposed methodological solutions for dependent left truncation, these make strong parametric assumptions that are untestable from observed data, and generally do not extend to multivariate regression modeling.¹¹

In this work, we design and implement simulation studies of analyses involving survival data subject to dependent left truncation, based on studies with real world clinico-genomic data, where patients are only observed upon receiving a genomic test, and survival is typically measured from the start of a certain treatment. Given the lack of commonly-accepted methods for dependent left truncation, we quantify the inferential bias that occurs when fitting risk set adjusted Cox regression and Kaplan-Meier estimators. We characterize general trends in the bias, with the goal of determining when such analyses may still provide useful results. In addition, we provide a procedure for conducting sensitivity analyses given an arbitrary dataset subject to dependent left truncation. This can be used by analysts to determine how bias in results would change when varying non-estimable parameters.

2. Methods

In this section, we apply a simulation approach to study the bias induced from dependent left truncation when applying standard and risk set adjusted methods. We first describe how to design a simulation study informed by a particular dataset, where most parameters can be estimated and others can be varied as a sensitivity analysis. We then apply this framework to conduct a simulation study; two additional analytic settings can be found in the Supplement.

2.1 Simulation-based sensitivity analysis

The goal of our method is to assess the expected bias due to dependent left truncation when estimating parameters of interest. We conduct the following steps to create a data-generating process that is congenial with the observed dataset:

- Assume generative models for survival, entry, and censoring
- Estimate parameters from observed dataset
- Vary parameters that are not estimable
- Perform simulation study

Most parameters in the simulation data-generating process can be estimated in order to match the dataset of interest. However, we vary the distributions of truncation and censoring across a range of parameters, since these are not estimable from dependently truncated data.

For illustrative purposes, we assume a survival analysis comparing two treatments, with both data arms subject to dependent left truncation. The estimand of interest is the marginal hazard ratio comparing the two treatments. For simplicity, we further assume that treatment is

unconfounded, although confounding variables can easily be added to the generative models for treatment arm assignment and survival time.

Assume generative models

The first step is to assume the form of the generative models that created the dataset. We describe a simple survival model that matches what we use in our simulation study described in the next section, although more complicated forms can also be used. Specifically, we assume

$$T \sim \text{Exponential}(\lambda_T)$$

$$\lambda_T = \lambda_{bh} \exp(\beta \text{trt} + \beta_E \text{entry}),$$

where λ_T is the hazard function for T the time to death, composed of the constant baseline hazard λ_{bh} with parameters β and β_E describing the conditional survival-treatment and survival-entry associations. We then assume the following models for treatment and entry times:

$$\text{trt} \sim \text{Bernoulli}(p)$$

$$\text{entry} \sim \{0 \quad \text{with probability } p_E$$

$$\{\text{Exponential}(\lambda_E) \text{ with probability } 1 - p_E$$

where p , λ_E and p_E are constant. Finally, we assume a model for censoring:

$$C \sim \text{Exponential}(\lambda_C)$$

$$\lambda_C = \lambda_T \eta_C,$$

where λ_C is the hazard function for C the time to censoring, and the parameter η_C results in a censoring probability of $\eta_C / (1 + \eta_C)$ in the non-truncated dataset. Then, the time-to-event is $Y = \min(T, C)$. Truncation is applied by filtering out observations where $Y < \text{entry}$.

Estimate parameters from dataset

Next, we estimate as many parameters for this generative model as we are able to do from our observed truncated dataset. Under our proportional hazards model assumption, the conditional model of survival time as a function of treatment arm and entry time is estimable; that is, estimates of λ_{bh} , β , and β_E can be obtained by fitting a risk set adjusted Cox model with treatment and entry time as regressors. Additionally, the probability of treatment p is readily estimable from the observed dataset, under our generative model for treatment, which is independent of entry time. Finally, the probability of pre-index entry to the cohort conditional on not being truncated, $P(\text{entry} = 0 \mid Y > \text{entry})$, is also estimable from the observed dataset. By conditional probability, we have that $p_E = P(\text{entry} = 0 \mid Y > \text{entry})P(Y > \text{entry})$, which allows us to recover an estimate for p_E once we set $P(Y > \text{entry})$ as described below.

The parameters η_C and λ_E , which characterize the censoring and entry time distributions, are not estimable from observed data, and therefore must be varied in simulation. We consider these as sensitivity parameters.

Vary parameters that are not estimable

Recall that the parameter of interest is the marginal hazard ratio comparing the two treatments. This would be estimated by fitting a standard Cox model on the non-truncated dataset, with treatment indicator as the sole regressor. However, because we only observe the truncated dataset, this parameter is not estimable under dependent left truncation. Under the data generating process, the marginal hazard ratio is a function of the entry time distribution. Therefore, as we vary λ_E , we are obtaining different true marginal hazard ratio parameters.

Varying η_c would affect the estimate of the marginal hazard ratio based on the non-truncated dataset.

We can select values for λ_E by choosing a parameter value that is more interpretable: the probability of a patient being truncated in the dataset. Each value of λ_E corresponds to a distinct entry time distribution, and therefore a distinct $P(Y < \text{entry})$ or truncation probability, assuming a fixed distribution of Y . We can then treat $P(Y < \text{entry})$ as the simulation parameter of interest, and select λ_E such that a given truncation probability is achieved. Because of the dependency of Y on entry , this probability is difficult to obtain in closed-form. However, it can be estimated by simulating many datasets with the same λ_E and computing the mean observed truncation proportion. Given a function that implements this procedure, a root-finding algorithm can then be applied in order to solve for the corresponding λ_E for a certain $P(Y < \text{entry})$. Larger values of the sensitivity parameters η_c and $P(Y < \text{entry})$ respectively correspond to greater prevalence of censoring and truncation in the population. Plausible ranges for these should be determined based on domain knowledge or external data. Then, for each parameter configuration, a simulation study can be performed to estimate the bias due to dependent left truncation.

Perform simulation study

For a particular data-generating process, we repeat the following steps over a large number of iterations:

- Generate non-truncated dataset
- Compute true parameter of interest

- Apply truncation and obtain truncated dataset
- Fit models to estimate parameter of interest
- Compute error metrics

Extensions

Though we have illustrated simulating a simple data-generating process here, it is straightforward to extend to more complex settings. If we suspected that there were differing levels of truncation between the arms, we could define separate entry time distributions, and vary both the corresponding truncation probabilities. Similarly, the dependence between survival and entry time can be allowed to differ between arms by adding an interaction term between treatment and entry time to the hazard function for T .

Additionally, while we assumed unconfounded treatment in the simulation data-generating process described above, this method can be extended to handle confounded treatment assignment. A measured confounder (or vector of confounders) X can be added to both the hazard function for T , and the model for probability of treatment. The relevant conditional regression parameters are estimable from the observed truncated data, and can be used for observational causal inference procedures. The subsequent simulation can proceed by incorporating e.g. inverse propensity score weighting into both the non-truncated and truncated analysis.

More flexible distributions can also be specified for the random variables in this framework. However, it is important to note that having entry time drawn from a single parameter distribution allows for the 1:1 correspondence between the parameter and the truncation probability. A

distribution with more parameters would lead to more sensitivity parameters that may be less interpretable.

2.2 Simulation study of dependent left truncation

In this section, we describe a simulation study conducted to characterize the bias induced through dependent left truncation in a real world control arm that is compared to a non-truncated treatment arm. This comparison of a non-truncated treatment arm to a real world control arm (rwCA) demonstrates a potential use for real world EHR-derived data^{12,13} where a treatment arm from e.g. a clinical trial is not subject to any delayed entry or left truncation, while the real world control arm used for comparison is. The estimand of interest is the marginal hazard ratio of death comparing the two treatments. We also considered two additional designs corresponding to common survival analyses performed with real world data subject to left truncation, which we have detailed in the Supplement.

We describe the parameters used below. In general, these were set to realistic real-world values based on corresponding parameters observed in the nationwide (US-based) de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database. The de-identified data originated from approximately 280 US cancer clinics (~800 sites of care). Retrospective longitudinal clinical data were derived from electronic health record (EHR) data, comprising patient-level structured and unstructured data, curated via technology-enabled abstraction, and were linked to genomic data derived from FMI comprehensive genomic profiling (CGP) tests in the FH-FMI CGDB by de-identified, deterministic matching.¹⁴ Genomic alterations were identified via comprehensive genomic profiling (CGP) of >300 cancer-related genes on FMI's next-generation sequencing (NGS) based FoundationOne® panel.^{15,16} To date, over 400,000 samples have been sequenced from patients across the US.

As in Section 2.1, we begin with the following model for survival time:

$$T \sim \text{Exponential}(\lambda_T)$$

$$\lambda_T = \lambda_{bh} \exp(\beta \text{trt} + \beta_E \text{entry}),$$

where λ_T is the hazard function for T the time to death, composed of the constant baseline hazard λ_{bh} with parameters β and β_E describing the conditional survival-treatment and survival-entry associations. The parameters were then set as follows:

- We set λ_{bh} to be 1/12, which corresponds to an average survival time of 12 months for patients on the $\text{trt} = 0$ arm who entered the cohort at their index time.
- The parameter β was set to $\log(0.8)$, which implies that patients on the $\text{trt} = 1$ arm have 80% of the hazard of death compared to patients on the $\text{trt} = 0$ arm who entered the cohort at the same time.
- β_E is the parameter describing the association between survival and entry time, i.e. the dependency of the left truncation mechanism. We varied this parameter among $\log(1, 1.01, 1.03, 1.05, 1.10)$.

We then use the following models for treatment and entry times, where patients with $\text{trt} = 1$ are not subject to any delayed entry, and therefore cannot be left truncated:

$$\text{trt} \sim \text{Bernoulli}(p)$$

$$\begin{aligned} \text{entry} &\sim \begin{cases} 0 & \text{if } \text{trt} = 1 \\ 0 & \text{if } \text{trt} = 0 \text{ with probability } p_E \\ \text{Exponential}(\lambda_E) & \text{if } \text{trt} = 0 \text{ with probability } 1 - p_E, \end{cases} \end{aligned}$$

and set the parameters as:

- p is fixed at 0.5
- p_E is fixed at 0.2

- λ_E is varied among values that resulted in left truncation probabilities

$P(Y > \text{entry} \mid \text{trt} = 0)$ of 0.1, 0.2, ..., 0.7, given all the other parameters set

Finally, we set the censoring model as

$$C \sim \text{Exponential}(\lambda_C)$$

$$\lambda_C = \lambda_T \eta_C,$$

where λ_C is the hazard function for C the time to censoring, and the parameter η_C results in a censoring probability of $\eta_C / (1 + \eta_C)$ in the complete dataset (before truncation is applied). We fixed $\eta_C = 1$.

3. Results

In this section, we report the results of our simulation study conducted for one analytic setting; results from the additional simulation studies can be found in the Supplement. These reflect the parameter settings described in Section 2. Varying other parameters in the data-generating process (such as p_E , p , λ_{bh} , and β) did not meaningfully affect results.

In Figure 1, we display the coverage probability results for this setting with the same parameters as used previously; here, the truncation probability only applies to the real world control arm. We see that 95% confidence intervals for the risk set adjusted Cox hazard ratio provide valid coverage up to a left truncation prevalence of 0.4 at the highest strength of dependency. This implies that differential left truncation between treatment arms results in a more difficult parameter to estimate. The naive estimator performs much worse here, notably also given independent left truncation.




Figure 1. Coverage probability of 95% confidence intervals for treatment hazard ratio comparing a non-truncated arm to a real world arm across simulation settings.

Next, we display the relative bias results for the simulation parameters in Figure 2. As in the first setting, we see that risk set adjustment is unbiased with independent left truncation, and bias increases with truncation and dependency. An interesting result here is that the bias is uniformly upwards, meaning that the estimated hazard ratio is always larger than the true hazard ratio. This phenomenon makes sense in the presence of dependent left truncation. Intuitively, we expect observed patient entries would be earlier compared to the non-truncated entry time distribution. Then, given our data generating process, these patients are also more likely to have a lower hazard of death. Therefore, the estimated hazard ratio comparing the non-truncated treatment arm to the dependently truncated arm will be artificially inflated.




Figure 2. Relative bias for estimated treatment hazard ratio comparing a non-truncated arm to a real world arm across simulation settings.

Recall that the true hazard ratio is less than 1, implying a protective effect of the treatment over the control. In many applications, we would expect that this is the substantive hypothesis being tested; therefore, since the estimate is biased towards the null hypothesis, inference will be conservative.

4. Discussion

Through our simulation studies, we measured the impact of dependent left truncation on estimator bias. We reported results with varying probabilities of left truncation (i.e. the proportion of patients who were not observed in the sample due to being truncated) and dependence

between survival and entry time; varying other data-generating parameters did not meaningfully affect estimator bias. We found that results varied greatly between analytical settings and estimands, with relative parameters (hazard ratios) being subject to less bias than absolute parameters (median survival time, as shown in the Supplement). At the highest level of dependency assessed (entry time HR of survival = 1.1), confidence intervals for median survival time only had valid coverage up to 0.3 probability of truncation. Hazard ratio confidence intervals provided valid coverage more often, particularly when the level of truncation and survival-entry time dependency in both arms was the same (see Supplement). Even with valid coverage, however, bias can be substantial in point estimates subject to dependent left truncation.

When patients in a non-truncated treatment arm given a protective treatment are compared to a dependently truncated cohort treated in a real world setting, the resulting bias in the hazard ratio is directionally upwards, or towards the null. This is expected, given the survivorship bias (i.e. artificially lower hazard in the truncated cohort) that cannot be corrected via risk set adjustment. The resulting inference is then conservative since the treatment effect is more likely to be declared non-significant. Therefore, if a non-truncated treatment arm shows a significantly lower hazard of death compared to the real world arm, a decision to advance the treatment development can be made with confidence. In drug development, conservative inference is usually preferable to the bias being directionally away from the null, which would lead to a greater likelihood of false positive results. We therefore conclude that there exist analyses where bias due to dependent left truncation may be acceptable in direction or in magnitude.

Our simulation approach shows general trends in estimator performance given dependent left truncation; however, the settings will not apply to all possible data analyses. Therefore, we also generalized this simulation study into a sensitivity analysis procedure that can be applied to any

arbitrary dataset subject to dependent left truncation. Under the Cox proportional hazards model assumption, many of the corresponding generative model parameters are estimable from data; the parameters determining the censoring and truncation probabilities are generally not. These can instead be varied across a reasonable grid determined by domain knowledge or comparisons to external datasets that are not truncated. Then, for each parameter configuration, the simulation procedure can estimate the level of bias expected to then inform how accurate the initial analysis on the observed dataset is. This method applies to a variety of common estimands, including hazard ratios (that may be conditional on baseline covariates, or marginal over the target population) or median survival time. We recommend that this approach be used by analysts to better quantify uncertainty around results when dependent left truncation is present.

A limitation of our work is that accurate bias quantification requires knowledge of the population truncation proportion, which is not estimable from a truncated dataset. We treat this as a varying sensitivity parameter, which results in a range of bias estimates. However, this range may be too wide to provide useful information. In practice, we suggest that plausible estimates of the truncation proportion be determined through domain knowledge or external data that is not subject to truncation. Our method also does not provide guidance as to what level of bias is considered low enough in order to draw conclusions from an analysis subject to dependent left truncation; this would vary among different applications. An expected relative bias of 10% in the treatment hazard ratio may not affect decision making in a phase I single arm trial, but could be of greater concern for a final regulatory decision.

This study is the first to our knowledge, to quantify the bias resulting from applying standard survival analysis techniques (i.e. Cox proportional hazards models and Kaplan-Meier estimators) with risk set adjustment to left truncated data. Although more complex models have

been proposed to account for dependent left truncation, they require unverifiable parametric assumptions, are not commonly used in practice, or do not extend to regression modeling.^{11,17} Another common strategy for handling left truncated data is to restrict the sample to only include subjects who satisfied the conditions for cohort entry before their index time. This eliminates delayed entry (and therefore left truncation) by design, and resulting survival analyses are no longer subject to bias. However, this changes the parameter being estimated; rather than estimating marginal hazard ratios or survival distributions, we are now estimating parameters conditional on entry before index. This results in inference on a population which may not be of scientific interest. In summary, in light of the lack of available methods for mitigating bias from left truncation, it is of interest to determine how reliable standard methods are for estimating marginal parameters under dependent left truncation.

References

1. Agarwala V, Khozin S, Singal G, et al. Real-world evidence in support of precision medicine: Clinico-genomic cancer data as A case study. *Health Aff (Millwood)*. 2018;37(5):765-772. doi: 10.1377/hlthaff.2017.1579 [doi].
2. Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left truncation. *Am J Epidemiol*. 2007;165(4):444-452. doi: kwk027 [pii].
3. Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: A prospective cohort study in western kenya. *Malar J*. 2015;14:461-6. doi: 10.1186/s12936-015-0950-6 [doi].
4. Keiding N, Moeschberger M. Independent delayed entry. In: Klein JP, Goel PK, eds. *Survival analysis: State of the art*. Dordrecht: Springer Netherlands; 1992:309-326. https://doi.org/10.1007/978-94-015-7983-4_18. 10.1007/978-94-015-7983-4_18.
5. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. *J Natl Cancer Inst*. 2013;105(19):1456-1462. doi: 10.1093/jnci/djt211 [doi].
6. Cain KC, Harlow SD, Little RJ, et al. Bias due to left truncation and left censoring in longitudinal studies of developmental and disease processes. *Am J Epidemiol*. 2011;173(9):1078-1084. doi: 10.1093/aje/kwq481 [doi].
7. Tsai W, Jewell NP, Wang M. A note on the product-limit estimator under right censoring and left truncation. *Biometrika*. 1987;74(4):883-886. <http://www.jstor.org/stable/2336484>. doi: 10.2307/2336484.
8. Mackenzie T. Survival curve estimation with dependent left truncated data using cox's model. *Int J Biostat*. 2012;8(1):/j/ijb.2012.8.issue-4679.1312. doi: /j/ijb.2012.8.issue-1/1557-4679.1312/1557-4679.1312.xml [pii].
9. Martin EC, Betensky RA. Testing quasi-independence of failure and truncation times via

conditional kendall's tau. *null*. 2005;100(470):484-492.

<https://doi.org/10.1198/016214504000001538>. doi: 10.1198/016214504000001538.

10. Kehl KL, Schrag D, Hassett MJ, Uno H. Assessment of temporal selection bias in genomic testing in a cohort of patients with cancer. *JAMA Netw Open*. 2020;3(6):e206976. doi: 10.1001/jamanetworkopen.2020.6976 [doi].

11. Chaieb LL, Rivest L, Abdous B. Estimating survival under a dependent truncation. *Biometrika*. 2006;93(3):655-669. <http://www.jstor.org/stable/20441314>.

12. Carrigan G, Whipple S, Taylor MD, et al. An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database. *Pharmacoepidemiol Drug Saf*. 2019;28(5):572-581. doi: 10.1002/pds.4758 [doi].

13. Davies J, Martinec M, Delmar P, et al. Comparative effectiveness from a single-arm trial and real-world data: Alectinib versus ceritinib. *J Comp Eff Res*. 2018;7(9):855-865. doi: 10.2217/cer-2018-0032 [doi].

14. Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with Non–Small cell lung cancer using a clinicogenomic database. *JAMA*. 2019;321(14):1391-1399. <https://doi.org/10.1001/jama.2019.3241>. Accessed 7/28/2021. doi: 10.1001/jama.2019.3241.

15. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol*. 2013;31(11):1023-1031. <https://doi.org/10.1038/nbt.2696>. doi: 10.1038/nbt.2696.

16. Foundation medicine. Foundation Medicine Web site. <https://www.foundationmedicine.com/info/about-our-products-and-services>. Updated 2021. Accessed July 28, 2021.

17. Chiou SH, Austin MD, Qian J, Betensky RA. Transformation model estimation of survival under dependent truncation and independent censoring. *Stat Methods Med Res*.

2019;28(12):3785-3798. doi: 10.1177/0962280218817573 [doi].

Tables

Table 1. Summary of simulation designs implemented, with truncation mechanisms and parameters of interest specified.

	Simulation design		
	NT arm + rwCA	Two RW arms	Single rWA
Treatment arm	No LT	No LT	LT
Control arm	LT	LT	
Estimand	Hazard ratio	Hazard ratio	Median survival time